FDA expands Mounjaro approval to reduce cardiovascular risk

The FDA has approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events, including cardiovascular death, nonfatal heart attack or nonfatal stroke, in adults with type 2 diabetes who are at high risk for these events. The approval was based on Surpass-Cvot, a trial that enrolled more than 13,000 participants across 30 countries […] The post FDA expands Mounjaro approval to reduce cardiovascular risk appeared first on Becker's Hospital Review | Healthcare N...